【摘要】 目的：探讨黄连素与口服益生菌制剂联用对腹泻型肠易激综合征（diarrhea-predominant irritable bowel syndrome,IBS-D）的干预效果，为临床上两药联用的可能性提供实验依据。方法：建立番泻叶灌胃联合束缚刺激诱导的IBS-D小鼠模型，单独或联合给予黄连素、口服益生菌制剂治疗后，以体重变化率、Bristol粪便性状评分、腹壁撤退反射评分、结肠组织病理学变化以及肠道菌群变化为指标，评价药物的干预效果。结果：黄连素单用及联合口服益生菌制剂均能降低Bristol粪便性状评分和腹壁撤退反射评分（P<0.05），而单用口服益生菌制剂在恢复IBS-D小鼠体重增长方面有一定的优势（P<0.05）。结肠组织病理切片观察显示，用药后均能减轻结肠的炎症范围。肠道菌群定量分析结果显示，黄连素与口服益生菌制剂联用能提高双歧杆菌属和乳杆菌属的相对含量（P<0.05），降低大肠杆菌的相对含量（P<0.05）。结论：黄连素与口服益生菌制剂联用未显示出拮抗作用，在改善肠道菌群失调上具有一定的增强作用。更多还原

【Abstract】 Objective: To investigate the intervention effect of the combination of berberine and oral probiotic formulations on diarrhea-predominant irritable bowel syndrome(IBS-D), and to provide an experimental basis for the possibility of combining the two drugs in clinical practice. Methods: A senna gavage combined with restraint stimulation-induced IBS-D mouse model was established, and after treatment with berberine and oral probiotic formulations alone or in combination, the rate of weight change, Bristol stool score, abdominal withdrawal reflex(AWR) score, colonic histopathological changes and intestinal flora changes were used as indicators to evaluate the intervention effects of drugs. Results: Berberine alone and in combination with oral probiotic formulations reduced Bristol stool score and AWR score(P<0.05), while oral probiotic formulations alone showed an advantage in restoring weight gain in IBS-D mice(P<0.05). Observation of histopathological sections of the colon showed that all medications reduced the extent of inflammation in the colon. Quantitative analysis of intestinal flora showed that the combination of berberine and oral probiotic formulations increased the relative content of Bifidobacterium and Lactobacillus(P<0.05) and decreased the relative content of Escherichia coli(P<0.05).Conclusion: The combination of berberine and oral probiotic formulations has no antagonistic effects and has some enhancement in improving intestinal flora dysbiosis.更多还原